Navigation Links
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/31/2009

PARIS, August 31 /PRNewswire-FirstCall/ --

- SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

Otamixaban is a first in class, rapid onset antithrombotic compound, acting as a direct selective inhibitor of factor Xa. Otamixaban is originating from sanofi-aventis world-class thrombosis research portfolio and is currently in phase IIb clinical development phase.

"The data show that intermediate dosages of otamixaban may offer substantial reduction in major coronary complications in patients presenting with acute coronary syndrome, with bleeding rate comparable to current therapy," said Dr Marc Sabatine, MD, MPH, an Investigator in the TIMI Study Group and a cardiologist at Brigham and Women's Hospital, Harvard Medical School. "This research is addressing an important medical need, by potentially significantly improving outcomes of ACS patients undergoing PCI while simplifying the treatment pattern of the acute management phase of the disease," he added.

The double-blind phase
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
2. Sanofi-aventis Stands Behind the Safety of Lantus(R)
3. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
8. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
9. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
10. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
11. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.C. , April 24, 2015  New ... ability of consumers to educate themselves about products ... the tools and techniques available to market researchers ... the changing consumer marketplace, it,s imperative that organizations ... to better identify market opportunities, niches and growth ...
(Date:4/24/2015)... 24, 2015   Vestagen Technical Textiles, Inc. ... , has recently received two notable innovation awards. The ... that recognizes innovations with potential to create a positive ... in New York City , VESTEX ... "Protection & Safety" category. The awards honor excellence in ...
(Date:4/24/2015)... Boston Scientific Corporation (NYSE: BSX ) is ... Annual Healthcare Conference on May 6 in Boston ... president and chief financial officer, and Susie Lisa , ... and answer session regarding the company with the host analyst ... of the presentation and question and answer session will be ...
Breaking Medicine Technology:Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference 2
... -- La Jolla,Pharmaceutical Company today announced updated interim ... Riquent(R) (abetimus,sodium), its drug candidate for systemic lupus ... previous,conclusion that there is a definitive and significant ... 900 mg doses of Riquent compared,with placebo (p=0.0001). ...
... N.J., March 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corporation's ... a potent payload in antibody conjugates for ... the Handbook of Therapeutic,Antibodies. , In a ... Susanna,Rybak, Ph.D. summarizes preclinical research indicating that ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:4/25/2015)... ME (PRWEB) April 26, 2015 ... Canadian based integrative healthcare event. The Integrative Healthcare ... place October 23-24, 2015 at the Sheraton Parkway ... Symposium Canada is one of the most anticipated ... clinically relevant, evidenced-based CME program. The event aims ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Illinois (PRWEB) April 25, 2015 ... enrichment and wellness, management and operations, and sales ... Meeting and Exhibition scheduled to be held from ... , LeadingAge Illinois is the largest eldercare association ... providers of services for older adults, including senior ...
(Date:4/25/2015)... April 25, 2015 For thirteen years, the ... income protection education event in the nation! This year, on ... Plus Group, US to take DI Day on the road ... G. Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer ... Day reflects on the change by stating, "The first Twin ...
(Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... from the University of Hull has told the British Psychological ... eating chocolate, lazing in front of the television, or going ... could make them more susceptible to disease.Those on the other ... to fight off infection.// ,Researchers asked 30 students ...
... a new gel, which works in a similar way to ... stomach each day, is being tested in four countries world-wide.For ... popping the contraceptive pill. But now there's a new option ... Association says "The gel is like any other gel, but ...
... in the devastated NewYork of America nor in the Afghanistan! It ... And who are the warring parties? They are the pharmaceutical industry ... Chemists Association. The latter is a member body of over 5,000 ... R Shah. // ,It is a classic case of ...
... Researchers in the US have found that genes contribute ... smoking. Chronic obstructive pulmonary disease (COPD), the name given ... because it leads to increasing shortness of breath. It's ... is a major cause of the problem.// ...
... the brain helps people recognise themselves in a picture, ... Deaconess Medical Center in Boston report their findings in ... a growing body of evidence that demonstrates the right ... self-awareness may provide unique insights into consciousness and doctors ...
... People who drink and smoke have to drink more ... greater risk of damage to their brains, livers and hearts, ... reduces blood alcohol levels in rats, which are considered a ... they will end up drinking more alcohol to get an ...
Cached Medicine News:Health News:The right is responsible 2
Straight shafts 4 mm platform. Wide serrated handle with dull finish. Platform angled 45 degrees....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade....
Fixed smooth rod which slides on skin. Designated most popular model or size....
Medicine Products: